Hamad Medical Corporation
hamad.qaTotal trials
132
Active
16
Phase 3
18
Total enrollment
222,009
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | — | — | 3 | ||
| Vitamin D Deficiency | — | — | — | — | — | 1 | |
| Human albumin | — | — | — | — | — | 1 |
Next readouts
- 2024-12
- 2025-07
- 2027-07-31
Top conditions
- COVID-196
- Bronchiolitis5
- Covid194
- Diabetes Mellitus4
- Extracorporeal Membrane Oxygenation Complication4
- COVID-19 Pneumonia3
- Asthma3
- Gastroenteritis3
Frequently asked questions about Hamad Medical Corporation
- How many clinical trials does Hamad Medical Corporation have on ClinicalTrials.gov?
- Hamad Medical Corporation is listed as the lead sponsor on 132 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hamad Medical Corporation's trials are in Phase 3?
- 18 of Hamad Medical Corporation's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Hamad Medical Corporation focus on?
- Hamad Medical Corporation's most-studied conditions on ClinicalTrials.gov are COVID-19, Bronchiolitis, Covid19, Diabetes Mellitus, Extracorporeal Membrane Oxygenation Complication.
- When are Hamad Medical Corporation's next clinical trial readouts?
- Hamad Medical Corporation has 3 upcoming primary-completion readouts tracked here; the soonest is “Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis”, expected around 2024-12.